Version 1
: Received: 6 May 2022 / Approved: 7 May 2022 / Online: 7 May 2022 (04:09:32 CEST)
How to cite:
Fekete, Z.; Suteu, P.; Gligor, L.; Todor, N.; Muntean, A.; Gherman, A.; Eniu, D. Fluctuation of Serum CEA in the Conventional Normal Range and The Risk of Relapse Following Curative Intent Treatment of Colorectal Cancer. Preprints2022, 2022050092. https://doi.org/10.20944/preprints202205.0092.v1
Fekete, Z.; Suteu, P.; Gligor, L.; Todor, N.; Muntean, A.; Gherman, A.; Eniu, D. Fluctuation of Serum CEA in the Conventional Normal Range and The Risk of Relapse Following Curative Intent Treatment of Colorectal Cancer. Preprints 2022, 2022050092. https://doi.org/10.20944/preprints202205.0092.v1
Fekete, Z.; Suteu, P.; Gligor, L.; Todor, N.; Muntean, A.; Gherman, A.; Eniu, D. Fluctuation of Serum CEA in the Conventional Normal Range and The Risk of Relapse Following Curative Intent Treatment of Colorectal Cancer. Preprints2022, 2022050092. https://doi.org/10.20944/preprints202205.0092.v1
APA Style
Fekete, Z., Suteu, P., Gligor, L., Todor, N., Muntean, A., Gherman, A., & Eniu, D. (2022). Fluctuation of Serum CEA in the Conventional Normal Range and The Risk of Relapse Following Curative Intent Treatment of Colorectal Cancer. Preprints. https://doi.org/10.20944/preprints202205.0092.v1
Chicago/Turabian Style
Fekete, Z., Alexandra Gherman and Dan Eniu. 2022 "Fluctuation of Serum CEA in the Conventional Normal Range and The Risk of Relapse Following Curative Intent Treatment of Colorectal Cancer" Preprints. https://doi.org/10.20944/preprints202205.0092.v1
Abstract
Carcinoembriogenic antigen (CEA) is a routine marker for follow-up of colo-rectal cancers. We aimed to determine whether a CEA increase within the normal range can be linked to a recurrence risk. We included 78 consecutive patients with colo-rectal cancer, who underwent curative surgical treatment with or without chemo- or radiotherapy. As reference, we used the smallest value of the CEA during follow-up. A total of 34/78 patients (43.6%) had fluctuations of CEA of at least 1.1 ng/ml, with or without increases above 5 ng/ml. In 27/34 patients (79.4%) increases of CEA were explained either by recurrence (15/34 patients, 44.1%), adjuvant chemotherapy (7/34 patients, 20.6%) or benign pathology (5/34 patients, 14.7%). In 5 of 22 recurrences (23%) a CEA increase of at least 1.1 ng/ml, but below 5 ng/ml preceded the clinical relapse by a median of 8 months (range 3-22 months). The 4-year disease-free survival was 89% in patients with postoperative CEA <2.5 ng/ml, and 55% in patients with CEA >2.5 ng/ml. CEA increase by at least 1.1 ng/ml within the normal range, after curative treatment of colorectal cancer can be either an early sign of relapse or can be usually explained by other pathological processes.
Keywords
CEA 1; colorectal cancer 2; follow-up 3; tumor markers 4; early intervention 5; adjuvant chemotherapy 6
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
